Boston Scientific (BSX) Non-Current Deferred Tax Liability (2009 - 2026)

Boston Scientific's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at $219.0 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 38.61% year-over-year to $219.0 million; the TTM figure through Mar 2026 stood at $219.0 million (up 38.61% YoY), while the FY2025 annual figure was $220.0 million, down 0.9% from the prior year.
• Non-Current Deferred Tax Liability came in at $219.0 million for Q1 2026 at Boston Scientific, roughly flat from $220.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $278.0 million in Q3 2022 to a low of $91.0 million in Q3 2023.
• A 5-year average of $188.6 million and a median of $210.0 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability surged 130.43% in 2022 and sank 67.27% in 2023, its largest moves.
• Boston Scientific's Non-Current Deferred Tax Liability stood at $144.0 million in 2022, then dropped by 6.94% to $134.0 million in 2023, then surged by 65.67% to $222.0 million in 2024, then declined by 0.9% to $220.0 million in 2025, then dropped by 0.45% to $219.0 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $219.0 million, $220.0 million, and $242.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison